[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341255-105":59,"doc-detail-341255-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","c5ar1-inhibition-reprograms-tumor-associated-macrophages-and-reverses-parp-inhibitor-resistance-in-breast-cancer","C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer","","Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) show clinical activity in multiple settings, yet responses are often transient, driving the need for effective combinations. Using two syngeneic murine breast cancer models that are intrinsically PARPi sensitive (T22) or resistant (T127), the study links tumor-associated macrophage (TAM) programs to differential drug sensitivity. Single-cell RNA sequencing identifies a TAM_C3 cluster enriched in resistant tumors via elevated Rps19/C5aR1 signaling; C5aR1 inhibition increases PARPi sensitivity, while C5aR1hi transfer decreases it.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/c5ar1-inhibition-reprograms-tumor-associated-macrophages-and-reverses-parp-inhibitor-resistance-in-breast-cancer/341255/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/c5ar1-inhibition-reprograms-tumor-associated-macrophages-and-reverses-parp-inhibitor-resistance-in-breast-cancer/341255.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What research question does the study address about PARP inhibitor therapy?","Question",{"text":112,"@type":113},"It investigates why tumor responses to PARP inhibitors differ between PARPi-sensitive and PARPi-resistant breast cancer models and what underlying mechanisms drive sensitivity versus resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study connect tumor-associated macrophages to PARP inhibitor response?",{"text":117,"@type":113},"Through single-cell RNA-sequencing, it identifies a TAM_C3 macrophage cluster enriched in PARPi-resistant tumors and shows this cluster is reduced by PARPi in sensitive tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does C5aR1 play in PARP inhibitor resistance according to the findings?",{"text":121,"@type":113},"Rps19/C5aR1 signaling is selectively elevated in the TAM_C3 cluster; inhibiting C5aR1 increases PARPi sensitivity, while transferring C5aR1hi cells decreases it.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341255,1790704454,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Article [https://doi.org/10.1038/s41467-024-48637-y](https://doi.org/10.1038/s41467-024-48637-y)  \nC5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer  \nReceived: 21 November 2022  \n\n| Accepted: 9 May 2024 |\n| --- |\n| |\n| Check for updates |\n\nXi Li 1,2 , Alfonso Poire 1, Kang Jin Jeong 1, Dong Zhang1,  \nTugba Yildiran Ozmen 1, Gang Chen2, Chaoyang Sun 2 & Gordon B. Mills 1  \nAlthough Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved in multiple diseases, including BRCA1/2 mutant breast cancer, responses are usually transient requiring the deployment of combination therapies for optimal efﬁcacy. Here we thus explore mechanisms underlying sensitivity and resistance to PARPi using two intrinsically PARPi sensitive (T22) and resistant (T127) syngeneic murine breast cancer models in female mice. We demonstrate that tumor associated macrophages (TAM) potentially contribute to the differential sensitivity to PARPi. By single-cell RNA-sequencing, we identify a TAM_C3 cluster, expressing genes implicated in antiinﬂammatory activity, that is enriched in PARPi resistant T127 tumors and markedly decreased by PARPi in T22 tumors. Rps19/C5aR1 signaling is selectively elevated in TAM_C3. C5aR1 inhibition or transferring C5aR1hi cells increases and decreases PARPi sensitivity, respectively. High C5aR1 levels inhuman breast cancers are associated with poor responses to immune checkpoint blockade. Thus, targeting C5aR1 may selectively deplete pro-tumoral macrophages and engender sensitivity to PARPi and potentially other therapies.  \nPoly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been extensively explored in the laboratory and the clinic based on synthetic lethality with defects in homologous recombination (HR) mediated by mutations in BRCA1/2 and other aberrations in the HR pathway. Although PARPi in combination with chemotherapy have been approved for management of BRCA-associated metastatic triplenegative breast cancer (TNBC)1,2, beneﬁts are not durable with almost universal recurrence. The mechanisms underlying PARPi resistance have been explored extensively and include BRCA1/2 reversion mutations, hypomorphic BRCA1/2 alleles, loss of hypermethylation of BRCA1/2, loss of the shieldin complex and activation of pro-survival pathways such as the MAPK and PI3K pathways3–7. However, taken together, the identiﬁed mechanisms can only explain PARPi resistance in a subset of patients8–10. In terms of extending the utility of PARPi to a wider population of TNBC patients, multiple clinical studies have  \ndemonstrated that PARPi combinations are active in patients whose do not have BRCA1/2 mutations or other aberrations in the HR pathway providing an opportunity to provide beneﬁt patients whose tumors do not have aberrations in BRCA1/29,11–19. Thus, there is a high priority for understanding resistance mechanisms to PARPi in tumors with and without BRCA1/2 mutations or aberrations in the HR pathway and identifying and implementing novel combinations therapies that are effective across mutational subtypes and that prevent the emergence of resistance or abrogate PARPi resistance once it occurs20,21.  \nMacrophages, innate immune cells derived from the myeloid lineage, exhibit remarkable epigenomic and transcriptomic plasticity driven, in part, by changes in the microenvironment22. Tumor associated macrophages (TAMs) can contribute to tumor clearance or protection based on their polarization into macrophages that mediate anti-tumor/pro-inﬂammatory or pro-tumor effects, respectively23. Pro-  \n1Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. 2Department of Obstetrics and  \nGynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. e-mail: xi[litongji@gmail.com](litongji@gmail.com)  \ninﬂammatory and pro-tumor TAMs mediate many oftheir pro and ","cbCaiuhkLE59OSxW","https://ap.wps.com/l/cbCaiuhkLE59OSxW","pdf",3283656,"English","# Abstract","[{\"question\":\"What research question does the study address about PARP inhibitor therapy?\",\"answer\":\"It investigates why tumor responses to PARP inhibitors differ between PARPi-sensitive and PARPi-resistant breast cancer models and what underlying mechanisms drive sensitivity versus resistance.\"},{\"question\":\"How does the study connect tumor-associated macrophages to PARP inhibitor response?\",\"answer\":\"Through single-cell RNA-sequencing, it identifies a TAM_C3 macrophage cluster enriched in PARPi-resistant tumors and shows this cluster is reduced by PARPi in sensitive tumors.\"},{\"question\":\"What role does C5aR1 play in PARP inhibitor resistance according to the findings?\",\"answer\":\"Rps19/C5aR1 signaling is selectively elevated in the TAM_C3 cluster; inhibiting C5aR1 increases PARPi sensitivity, while transferring C5aR1hi cells decreases it.\"}]","C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer | PDF",1790041139,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29ac3f8743d1fd578faebbddfd18c2a7.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ee06a44e01c5e077bdad15f3efeccf2.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14e2506c71bbfeb3939d69aaa4b45de2.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68420ae1942e218a7eb23cfb62a0e18d.webp",980,1301]